NCT06937775

Brief Summary

The aim of this study was to investigate the effects of rapid maxillary expansion on local and systemic oxidative stress levels. Thirty-five volunteer patients (17 females and 18 males) who needed rapid maxillary expansion will be included in the study. Serum and saliva samples will be collected from each patient during four different periods: a week before the treatment (T0), on the day of sutural separation (T1), at the end of the active expansion period (T2), and after the completion of a 3-month retention period (T3). To evaluate the patients' periodontal status, plaque index, gingival index, and probing pocket depth scores will be recorded for each period. 8-hydroxydeoxyguanosine (8-OHdG), total oxidative status (TOS), total antioxidant capacity (TAS), and oxidative stress index (OSI) biomarkers will be evaluated to determine the local and systemic oxidative stress levels.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2016

Shorter than P25 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 10, 2016

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 10, 2016

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 10, 2016

Completed
8.6 years until next milestone

First Submitted

Initial submission to the registry

March 29, 2025

Completed
24 days until next milestone

First Posted

Study publicly available on registry

April 22, 2025

Completed
Last Updated

July 24, 2025

Status Verified

April 1, 2025

Enrollment Period

2 months

First QC Date

March 29, 2025

Last Update Submit

July 21, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Biochemical analyses - 8-OHdG

    8-OHdG is the most frequently encountered and best known mutagenicity of more than 20 oxidative base damage products of ROS in DNA. Since it is easily detected in living cells and body fluids, it is the most commonly used oxidative DNA damage marker. Serum and saliva levels will be measured using a suitable ELISA kit (Cayman Chemical DNA/RNA Oxidative Damage ELISA Kit Item No.589320) according to the manufacturer's instructions. The measurement principle is as follows: It is based on the competition between 8-OHdG from the sample and 8-OHdG-acetylcholinestarase conjugate (8- OHdG Tracer) from the kit for a limited amount of 8-OHdG monoclonal antibody covering the plate well. The colour intensity measured spectrophotometrically at 410 nm is directly proportional to the tracer and inversely proportional to the amount of free 8-OHdG in the sample.

    a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

  • Biochemical analyses - Oxidative Stress Index (TOS/TAS=OSI)

    Total Oxidative Status (TOS) is a current method used to detect lipid peroxidation and oxidative stress. TOS is considered to be a superior method compared to other methods due to the impracticality of measuring different oxidant molecules individually and the inability to fully reflect the interaction of oxidant molecules with each other. Total Antioxidan Status (TAS) is a biochemical parameter obtained as a result of the sum of the antioxidant capacities of all antioxidants in the biological samples examined. Oxidative Stress Index (OSI) is a proportional value obtained by dividing TOS by TAS. It is directly affected by total oxidative and antioxidant status and reveals the final oxidative status in a practical and understandable way. OSI value was calculated according to the following formula. OSI = TOS (mmol H2O2 Equiv./L) / TAS (mmol Trolox Equiv./L) x 100

    a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

Secondary Outcomes (3)

  • Clinical Periodontal Assessments-plaque index

    a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

  • Clinical Periodontal Assessments-gingival index

    a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

  • Clinical Periodontal Assessments-probed pocket depth (PPD)

    a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)

Study Arms (4)

TO

OTHER

1 week before the placement of the Hyrax appliance

Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores )Other: Biochemical Sample Supply (Collection of serum and saliva samples)

T1

OTHER

The day of the first clinical observation of sutural opening (5-7 days after activation)

Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores )Other: Biochemical Sample Supply (Collection of serum and saliva samples)Procedure: Rapid maxillary expansion with Hyrax appliance

T2

OTHER

The day of completion of active expansion (3-4 weeks)

Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores )Other: Biochemical Sample Supply (Collection of serum and saliva samples)Procedure: Rapid maxillary expansion with Hyrax appliance

T3

OTHER

The day of completion of the 3-month reinforcement period

Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores )Other: Biochemical Sample Supply (Collection of serum and saliva samples)Procedure: Rapid maxillary expansion with Hyrax appliance

Interventions

Plaque index (PI), gingival index (GI) and probed pocket depth (PPD) scores will be recorded at T0, T1, T2 and T3 assessment periods to evaluate the periodontal status and oral care effectiveness of the participants. PPD is the distance between the gingival margin and the sulcus base. Measurements will be made at 6 different sites (mesio-vestibular, vestibular, disto-vestibular, mesio-oral, oral, disto-oral) of each tooth using a Williams periodontal probe (Hu Friedy, Chicago, Illinois, USA). During the measurements, care will be taken to position the probe as parallel as possible to the long axis of the tooth and not to apply excessive force.

T1T2T3TO

Serum and saliva samples will obtained from all individuals included in the study at T0, T1, T2 and T3 for biochemical analyses. For standardisation purposes, blood samples will be collected from the antecubital fossa with the patients in a sitting position. After resting for 30 minutes (min) at room temperature, the samples will be centrifuged (4ºC at 3000 rpm for 5 min) and serum samples will be obtained. The samples will be transferred into eppendorf tubes and stored in the freezer (-80ºC) until the study day. Sampling will be performed early in the morning. Participants will be warned not to consume anything other than water for the last 12 hours and not to brush their teeth that morning. Individuals will be left with their mouths open for 5 min to allow saliva to accumulate at the floor of the mouth. Unstimulated saliva samples accumulated at the floor of the mouth will be collected and transferred to eppendorf tubes.

T1T2T3TO

Rapid maxillary expansion (RME) is the most commonly preferred treatment of skeletal jaw stenosis in the transversal direction. Bilateral anchorage is the process of increasing the transversal dimension of the midpalatal suture (sutura palatina media) by applying strong tensile forces in the lateral direction to the dentoalveolar structures of the teeth and/or palatal bone. The primary goal of treatment is to provide orthopedic movement through sutural separation.

T1T2T3

Eligibility Criteria

Age11 Years - 16 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Being between 11-15 years of age,
  • Having an indication for maxillary expansion due to maxillary stenosis,
  • Being highly cooperative, performing adequate oral care,
  • Being periodontally healthy,
  • Not having cleft lip and/or palate anomalies,
  • Not having any systemic disease,
  • Not having used any medication including antibiotics and anti-inflammatory drugs in the last 6 months,
  • Not being substance addicted and not smoking.

You may not qualify if:

  • Having inadequate oral hygiene
  • Being periodontally unhealthy
  • Having cleft lip and/or palate anomalies,
  • Having any systemic disease,
  • Having used any medication including antibiotics and anti-inflammatory drugs in the last 6 months,
  • Being substance addicted and not smoking.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Dental Plaque IndexPeriodontal Index

Intervention Hierarchy (Ancestors)

Dental Health SurveysHealth SurveysSurveys and QuestionnairesData CollectionEpidemiologic MethodsInvestigative TechniquesDentistryHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public HealthPublic Health DentistryPeriodontics

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assoc. Prof. Dr.

Study Record Dates

First Submitted

March 29, 2025

First Posted

April 22, 2025

Study Start

January 10, 2016

Primary Completion

March 10, 2016

Study Completion

August 10, 2016

Last Updated

July 24, 2025

Record last verified: 2025-04